- Price
- $19.54
- Day
- +4.05%
- Mkt Cap
- $3.42B
- 52W Range
- $3.03 – $20.79
- Volume
- 1.90M
- Beta
- 1.68
Find a company by name or ticker and open its page
Snapshot of fundamentals, performance, and 5D scores.
Business fundamentals and company information
Recent price action and historical returns
How the business makes money, by product and geography
Five lenses on the stock. Click any card to dive deeper.
How to read these dimensions
The five dimensions are independent lenses on a company, not a single combined score. Read them together rather than in isolation: where one dimension scores differently from the others is often the most useful place to focus your own research. Each score is built from rules and weights you can adjust, so treat them as a transparent starting point for your analysis, not a recommendation to buy or sell.
Recent news headlines and analyst price-target moves
Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026
CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, will report second quarter 2026 financial results and corporate highlights after the U.S. financial markets close on Thursday, August 6, 2026.
Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy?
Relay Therapeutics (RLAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers
/PRNewswire/ -- For years, the promise of artificial intelligence in drug discovery has been easy to describe and hard to monetize. Plenty of companies can